Atlas Trials

Hereditary Angioedema (HAE)

58 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Hereditary Angioedema (HAE)

RecordFirmDate
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) (NCT05460325)Takeda2022-06-22
A Survey of Lanadelumab in Participants With Hereditary Angioedema (NCT05397431)Takeda2022-05-30
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland (NCT05147181)Takeda2022-03-11
A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis (NCT04861090)Takeda2021-09-15
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II (NCT04130191)Shire2019-12-11
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America (NCT03845400)Shire2019-03-30
Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan (NCT03873116)BioCryst Pharmaceuticals2018-12-27
FIRAZYR General Drug Use-Results Survey (Japan) (NCT04057131)Shire2018-11-20
Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema (NCT03240133)BioCryst Pharmaceuticals2017-07-31
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) (NCT02865720)Shire2016-09-08
Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema (NCT02870972)BioCryst Pharmaceuticals2016-08-01
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE (NCT02741596)Shire2016-05-26
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE (NCT02586805)Shire2016-03-03
Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects (NCT02663687)Shire2016-02-19
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema (NCT02584959)Shire2015-11-01
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants (NCT03888755)Shire2015-03-18
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants (NCT02093923)Shire2014-05-14
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema (NCT02052141)Shire2014-03-20
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers (NCT02045264)Shire2014-02-21
A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects (NCT01923207)Shire2013-08-12
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks (NCT01756157)Shire2013-02-04
Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema (NCT01253382)Shire2012-06-01
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema (NCT01541423)Shire2012-05-11
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema (NCT01386658)Shire2012-01-27
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 (NCT01095510)Shire2010-06-02
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema (NCT01059526)Shire2010-02-01
Firazyr® Patient Registry (Icatibant Outcome Survey - IOS) (NCT01034969)Shire2009-07-10
Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) (NCT00456508)Shire2007-04-01
Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) (NCT00262080)Shire2005-12-31
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema (NCT01826916)Shire2003-11-01
Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults (NCT04583007)Shire
Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 Study (NCT07159464)CSL Behring

Track Hereditary Angioedema (HAE) automatically

Every clearance here is in the API, with alerts when new ones post.